Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)

Eligible applicants include federal government agencies, faith-based and community-based organizations, Indian/Native American tribal governments (including non-federally recognized), non-domestic (foreign) entities, regional organizations, and U.S. territories or possessions. For a complete and current list of eligible organization types and any additional requirements, please visit the official NIH or relevant federal agency website where this NOFO is posted.

This grant program provides funding up to $3,000,000. The exact award amount may vary depending on the scope of your proposed research, project phase, and available funding in each cycle. Check the official funding opportunity announcement for details on budget requirements and variations by year.

Applications are typically submitted through Grants.gov or the NIH eRA system, depending on the administering agency. You will need to prepare a comprehensive research proposal outlining your intervention, research design, timeline, and budget. The UG3/UH3 structure often includes a planning phase (UG3) followed by a full implementation phase (UH3). Visit the official NOFO on the NIH or relevant federal agency website for detailed submission instructions, formatting requirements, and the application deadline.

Funding supports research on discovery and development of interventions to prevent and/or treat substance use disorders and overdose. This includes preclinical research, clinical research studies, medication development, medical device development, and treatments for co-morbid SUDs. Research should focus on high-impact work with rapid results that advance candidate interventions toward regulatory approval or clinical adoption. Clinical trials are optional under this mechanism. Consult the official NOFO for detailed information on allowable uses and budget categories.